Such HRAS mutations have been consistently observed in several types of cancer, including squamous cell carcinoma of the head and neck, bladder cancer, and thyroid carcinoma (Jefferies and Foulkes, 2001; Gilardi et al., 2020). Here, HRAS is linked to urinary bladder carcinoma.